Prognostic importance of cytogenetic subgroups in de novo pediatric acute nonlymphocytic leukemia.

Kalwinsky, David K.; Raimondi, Susana C.; Schell, Michael J.; Mirro, Joseph; Santana, Víctor M.; Behm, Frederick G.; Dahl, Gary V.; Williams, Dorothy L.

doi:10.1200/jco.1990.8.1.75

Cited by 122 publications

(88 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[16][17][18][19] The annual incidence of childhood AML is 5.4/million vs 4.0 for MDS. 1 Thus, the ratio of MDS vs AML should, accepting the Danish population-based figures, be 4.9.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7

et al. 1999

View full text Add to dashboard Cite

We reviewed the clinical features, treatment, and outcome of 100 children with myelodysplastic syndrome (MDS), juvenile myelomonocytic leukemia (JMML), and acute myeloid leukemia (AML) associated with complete monosomy 7 (−7) or deletion of the long arm of chromosome 7 (7q−). Patients with therapyinduced disease were excluded. The morphologic diagnoses according to modified FAB criteria were: MDS in 72 (refractory anemia (RA) in 11, RA with excess of blasts (RAEB) in eight, RAEB in transformation (RAEB-T) in 10, JMML in 43), and AML in 28. The median age at presentation was 2.8 years (range 2 months to 15 years), being lowest in JMML (1.1 year). Loss of chromosome 7 as the sole cytogenetic abnormality was observed in 75% of those with MDS compared with 32% of those with AML. Predisposing conditions (including familial MDS/AML) were found in 20%. Three-year survival was 82% in RA, 63% in RAEB, 45% in JMML, 34% in AML, and 8% in RAEB-T. Children with −7 alone had a superior survival than those with other cytogenetic abnormalities: this was solely due to a better survival in MDS (3-year survival 56 vs 24%). The reverse was found in AML (3-year survival 13% in −7 alone vs 44% in other cytogenetic groups). Stable disease for several years was documented in more than half the patients with RA or RAEB. Patients with RA, RAEB or JMML treated with bone marrow transplantation (BMT) without prior chemotherapy had a 3-year survival of 73%. The morphologic diagnosis was the strongest prognostic factor. Only patients with a diagnosis of JMML fitted what has previously been referred to as the monosomy 7 syndrome. Our data give no support to the concept of monosomy 7 as a distinct syndrome.

show abstract

“…[16][17][18][19] The annual incidence of childhood AML is 5.4/million vs 4.0 for MDS. 1 Thus, the ratio of MDS vs AML should, accepting the Danish population-based figures, be 4.9.…”

Section: Discussionmentioning

confidence: 99%

“…4,5,15 Only 4-5% of childhood AML cases show −7/7q−. [16][17][18][19] AML patients with −7/7q− have a very poor prognosis, 16,17,19 but due to the infrequency of the association there are very few data on the clinical characteristics of these patients.…”

Section: Introductionmentioning

confidence: 99%

Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7

et al. 1999

View full text Add to dashboard Cite

show abstract

“…The incidence of 11q23 anomalies in our series is in accordance with previous reports. [31][32][33][34][35] This cytogenetic recently reported in combination with CD15 and cytoplasmic myeloperoxidase in numerous ANLL subsets 24 including M2-abnormality was also described in B lineage ALL, exhibiting in some cases myeloid features at diagnosis with expression ANLL with t(8;21). 16 Such an asynchronous expression of CD34 with myeloid differentiation antigens suggests a disby blast cells of CD15 or CDw65 antigens or relapsing with a myeloid phenotype.…”

Section: M4mentioning

confidence: 99%

Immunophenotypic patterns and cytogenetic anomalies in acute non-lymphoblastic leukemia subtypes: a prospective study of 432 patients

Casasnovas¹,

Campos

Mugneret³

et al. 1998

Leukemia

View full text Add to dashboard Cite

This study prospectively analysed the relationships between observed to vary according to the type and number of lymphimmunophenotypic and cytogenetic features of blast cells in oid lineage antigens expressed. 9 The expression of some of 432 acute non-lymphoblastic leukemias (ANLL) at presentation.these antigens also appeared to be related to recurrent cyto- The study was initiated in March 1992 by the Groupe d'Etude Immunologique des Leucémies (GEIL), a French multicentric Introduction group that collects data from over 40 centers in France and Belgium. The endpoint of the present analysis was 30 SepIn 1988, the morphologic, immunologic and cytogenetic tember 1994. Patients eligible for the study met the following working classification (MIC) of acute non-lymphoblastic leucriteria: established diagnosis of ANLL and collection of a sufkemia (ANLL) 1 underlined the correlations between some ficient number of blast cells for both immunophenotype and recurrent specific cytogenetic abnormalities and defined cytosuccessful cytogenetic analysis. M0-ANLL were defined as logic subgroups. At that time, the relationships between cytopreviously reported. 2 FAB data were collected from each genetic features identified in ANLL and the immunophenotype center's cytology laboratory. of blast cells remained poorly characterised. During the last 10 years, immunophenotypic analysis of ANLL blast cells has provided new information and become a powerful tool in Immunological phenotyping assigning undifferentiated acute leukaemia to the myeloid lineage. 2 Meanwhile, investigation of lymphoid lineage antigens Mononuclear cells were recovered from heparinized bone on blast cells from a large number of ANLL has demonstrated marrow (391 cases) or peripheral blood (41 cases) collected the high immunophenotypic heterogeneity of morphologically at diagnosis. The percentage of blast cells after separation on and cytogenetically well-defined diseases. [3][4][5][6][7][8] a Ficoll gradient was higher than 50% in M2 and M4 subtypes Molecular analyses attempting to correlate these immunoand higher than 80% in the remaining cases. The immunophenotypic features to their genotypic counterpart did not phenotype was performed by flow cytometry on blast cells demonstrate any strict correlation between the rearrangement gated on their abnormal light scatter characteristics, using of immunoglobulin and T cell receptor genes and the monoclonal antibodies for the following antigens: CD9 expression of lymphoid lineage antigens on ANLL blast (IOB2), CD11b (FD11), CD13 (MY7), CD14 (UCHM1), cells. 3,9-11 However, the prevalence of genotypic changes was CD15a (SMY15a), CD16 (Leu11b), CD18 (IOT18), CD33 (MY9), CD34 (BI-3C5), CD35 (44-D), CD36 (OKM5), CDw65 (VIM2), CD41 (P2), CD42 (SZ2), T lymphoid differentiation

show abstract

“…Children with t(9;11)(p22;q23)-associated AML were reported to have a favorable prognosis. [27][28][29] Adults with t(9;11)(p22;q23)-associated AML had a better treatment outcome than adults with other 11q23 translocation-associated AML. 30 The partner gene, AF9, 31 which juxtaposes to MLL, may influence the favorable prognosis of patients with t(9;11) AML.…”

Section: Discussionmentioning

confidence: 99%

True

1999

Leukemia

View full text Add to dashboard Cite

Of 29 infants with acute myeloid leukemia (AML), 14 (48%) had various 11q23 translocations. MLL rearrangements were examined in 21 of the 29 patients, and 11 (52%) showed the rearrangements. 11q23 translocations and/or MLL rearrangements were found in 17 (58%) of the 29 patients. While all but one of the 17 patients with 11q23/MLL rearrangements had M4 or M5 type of the FAB classification, the 12 patients without such rearrangements had various FAB types, including M2, M4, M4EO, M6 and M7. Of the 12 patients with other chromosome abnormalities or normal karyotypes, two had inv(16) or t(16;16), one had t(1;22)(p13;q13), and two had a novel translocation, t(7;12)(q32;p13). The breakpoint on 12p of the t(7;12) was assigned to intron 1 or the region just upstream of exon 1 of the TEL/ETV6 gene by fluorescence in situ hybridization. The event-free survival at 5 years for the 17 patients with 11q23/MLL rearrangements was 42.2%, and that for the 12 patients without such rearrangements was 31.3% (P = 0.5544). 11q23/MLL rearrangements have been frequently reported and a poor prognosis in infant acute lymphoblastic leukemia implied. Our study showed that while 11q23/MLL rearrangements were also common in infant AML, AML infants with such rearrangements had a clinical outcome similar to that of AML infants without such rearrangements.

show abstract

Prognostic importance of cytogenetic subgroups in de novo pediatric acute nonlymphocytic leukemia.

Cited by 122 publications

References 16 publications

Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7

Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7

Immunophenotypic patterns and cytogenetic anomalies in acute non-lymphoblastic leukemia subtypes: a prospective study of 432 patients

True

Contact Info

Product

Resources

About